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SUMMARY
The biguanide drug metformin is widely prescribed
to treat type 2 diabetes and metabolic syndrome,
but its mode of action remains uncertain. Metformin
also increases lifespan inCaenorhabditis elegans co-
cultured with Escherichia coli. This bacterium exerts
complex nutritional and pathogenic effects on its
nematode predator/host that impact health and
aging. We report that metformin increases lifespan
by altering microbial folate and methionine metabo-
lism. Alterations in metformin-induced longevity by
mutation of worm methionine synthase (metr-1) and
S-adenosylmethionine synthase (sams-1) imply met-
formin-induced methionine restriction in the host,
consistent with action of this drug as a dietary re-
striction mimetic. Metformin increases or decreases
worm lifespan, depending on E. coli strain metformin
sensitivity and glucose concentration. In mammals,
the intestinal microbiome influences host metabo-
lism, including development of metabolic disease.
Thus, metformin-induced alteration of microbial
metabolism could contribute to therapeutic effi-
cacy—and also to its side effects, which include
folate deficiency and gastrointestinal upset.
INTRODUCTION
Metformin is the world’s most widely prescribed drug, as an oral
antihyperglycemic agent for type 2 diabetes (T2D) and in the
treatment of metabolic syndrome. However, the real and poten-
tial benefits of metformin therapy go beyond its prescribed
usage, including reduced risk of cancer (Dowling et al., 2011)
and, in animal models, delayed aging, an effect seen in rodents
(Anisimov et al., 2011) and in the nematode Caenorhabditis ele-
gans (Onken and Driscoll, 2010). The mechanisms underlying
these positive effects remain unclear. One possibility is that met-
formin recapitulates the effects of dietary restriction (DR), the
controlled reduction of food intake that can improve late-life
health and increases lifespan in organisms ranging from nema-
todes and fruit flies to rodents and rhesus monkeys (Mair and
Dillin, 2008). In mammals, the action of metformin is partly medi-
ated by AMPK activation, which results in downregulation of
TOR and the IGF-1/AKT pathways to reduce energy-consuming
processes (Pierotti et al., 2012). An unexplored possibility is that
metformin alters mammalian physiology via its effects on gut
microbiota (Bytzer et al., 2001).
The gut microbiome (or microbiota) plays a major role in the
effects of nutrition on host metabolic status (Nicholson et al.,
2012), as well as contributing to metabolic disorders such as
obesity, diabetes, metabolic syndrome, autoimmune disorders,
inflammatory bowel disease, liver disease, and cancer (Delzenne
and Cani, 2011; Kau et al., 2011; Nicholson et al., 2012). It may
also influence the aging process (Ottaviani et al., 2011). It has
been argued that the host and its symbiotic microbiome acting
in association (holobiont) should be considered as a unit of
selection in evolution (Zilber-Rosenberg and Rosenberg, 2008).
Coevolution of microbiota facilitates host adaptation by enabling
e.g., nutrient acquisition, vitamin synthesis, xenobiotic detoxifi-
cation, immunomodulation, and gastrointestinal maturation. In
return, the host provides a sheltered incubator with nutrients
(Ba¨ckhed et al., 2005). Thus, the two components of the holo-
biont are symbiotic, but microbiota can also be commensal or
pathogenic.
Defining interactions between drug therapy, microbiome and
host physiology is experimentally challenging given the complex
and heterogeneous nature of mammalian gut microbiota. Here
simple animal models amenable to genetic manipulation can
be helpful. For example, in the fruit fly Drosophila, microbiota
modulates host development and metabolic homeostasis via
the TOR pathway (Storelli et al., 2011).
C. elegans is particularly convenient for such studies because
under standard culture conditions only a single microbe is
present (as a food source): the human gut bacterium Escherichia
coli (Brenner, 1974). Active bacterial metabolism is a critical
nutritional requirement for C. elegans, the absence of which re-
tards development and extends lifespan (Lenaerts et al., 2008).
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Moreover, worms are sometimes long-lived on mutant E. coli
with metabolic defects (Saiki et al., 2008; Virk et al., 2012) and
on microbial species thought to enhance human health, e.g.,
from the genera Lactobacillus and Bifidobacterium (Ikeda
et al., 2007). These observations suggest that E. coli plays
a more active role in C. elegans nutrition and metabolism than
as a mere food source, and in some respects acts as microbiota
(Lenaerts et al., 2008).C. elegans has also been used extensively
to identify genes that specify endocrine, metabolic, and dietary
regulation of aging (Kenyon, 2010).
In this study, we examine the mechanism by which metformin
extends lifespan in C. elegans. We report that its effects are
mediated by the cocultured E. coli, where metformin inhibits
bacterial folate and methionine metabolism. This, in turn, leads
to altered methionine metabolism in the worm, and increased
lifespan. These findings reveal how drug action on host-micro-
biome interactions can impact health and longevity.
RESULTS
Extension of C. elegans Lifespan by Metformin Is
Mediated by Live E. coli
We first verified the effects on worm lifespan of metformin, and
also the more potent biguanide drug phenformin. Metformin at
25, 50, and 100 mM increased mean lifespan by 18%, 36%,
and 3% (Figure 1A; Table S1 available online). Phenformin at
1.5, 3, and 4.5 mM also increased lifespan, by 5%, 21%, and
26% (Figure 1B; Table S1). As expected, maximal effects on life-
span of these pharmacologically similar drugs were nonadditive
0 mM
4.5 mM
3 mM
1.5 mM
10 200 30 40 50
0.2
0.4
0.6
0.8
1.0
0
Fr
ac
tio
n 
al
iv
e
B
C
0 mM
50 mM Metformin
4.5 mM Phenformin
4.5 mM Phenf. + 
50 mM Metf.
Wild type
0 mM
100 mM
50 mM
25 mM
Days
10 200 30 40 50
0.2
0.4
0.6
0.8
1.0
0
Fr
ac
tio
n 
al
iv
e
Wild type
Metformin
Phenformin
Day 8
0 mM
100 mM
50 mM
25 mM
10 200 30 40 50
A
Wild type
Metformin
60
0.2
0.4
0.6
0.8
1.0
0
Fr
ac
tio
n 
al
iv
e
10 200 30 40 50
0.2
0.4
0.6
0.8
1.0
0
Fr
ac
tio
n 
al
iv
e
Wild type
Metformin
E Days
10 200 30 40 50
- 2
- 4
- 6
- 8
0
Ln
 m
or
ta
lit
y
0 mM
50 mM
Wild type
Metformin
D
Figure 1. The Biguanide Drugs Phenfor-
min and Metformin Decelerate Aging in
C. elegans
(A and B) Metformin (A) and phenformin (B) extend
lifespan in a dose-dependent manner. Phenformin
alters fecundity and reduces body size (see
Figures S1A–S1D).
(C) Phenformin (4.5mM) does not increase lifespan
in the presence of 50 mM metformin, consistent
with similar mechanism of drug action.
(D) Metformin decreases the exponential increase
in age-related mortality (for survival curve see
Figure S1E).
(E) Later-life administration (day 8) of metformin
increases lifespan at lower concentrations (25, but
not 50 or 100 mM).
See also Figure S1. For statistics, see Table S1.
(Figure 1C; Table S1). Metformin reduced
the exponential age increase in mortality
rate (Figure 1D), demonstrating that it
slows aging (at least until day 18) rather
than reducing risk of death. Metformin
also modestly increased mean lifespan
when administered from middle age
onward, but only at 25 mM (+8%, p <
0.001; Figure 1E; Table S1). In most trials,
the DNA replication inhibitor FUdR was
used to prevent progeny production, but
effects of metformin on lifespan are not FUdR-dependent
(Figures S1F and S1G; Table S1) (Onken and Driscoll, 2010).
These results confirm the robust effects of biguanide drugs on
aging in C. elegans.
Interventions altering E. coli can affect C. elegans lifespan
(Garigan et al., 2002; Gems and Riddle, 2000; Saiki et al.,
2008). To test the possibility that metformin increases worm life-
span by altering the E. coli, we assessed its effects in the
absence of bacteria (axenic culture). As expected, culture on
axenic medium (Lenaerts et al., 2008) and bacterial deprivation
(Kaeberlein et al., 2006) caused an increase in worm lifespan,
typical of DR. Under these conditions, metformin did not in-
crease worm lifespan, but instead markedly reduced it (Figures
2A, S2A, and S2B; Table S2).
UV-irradiation of E. coli impairs bacterial viability and extends
worm lifespanwithout reducing fertility, suggesting amechanism
distinct from DR (Gems and Riddle, 2000). Under these condi-
tions, metformin still shortened lifespan (16%, p < 0.001; Fig-
ure 2B; Table S2). Next, we raised E. coli in the presence of
metformin and then transferred it to drug-free agar plates.
Drug pretreatment of E. coli robustly extended worm lifespan
(+33%, p < 0.001; Figure 2C; Table S2). We conclude that
the life-extending effect of metformin is mediated by live
E. coli. Moreover, in the absence of E. coli, metformin shortens
C. elegans lifespan, likely reflecting drug toxicity.
One possibility is that metformin extends worm lifespan by
reducing E. coli pathogenicity. Proliferating E. coli block the
alimentary canal in older worms, and antibiotic treatment can
both prevent this proliferation and increase worm lifespan
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(Garigan et al., 2002). To determine whether metformin extends
worm lifespan by preventing E. coli proliferation, we tested its
effects in the presence of carbenicillin. This antibiotic is bacterio-
static, blocking bacterial proliferation without greatly reducing its
viability. Metformin increased lifespan to a similar degree in the
absence (+25%) or presence (+24%) of carbenicillin (p < 0.001;
Figure 2D; Table S2). Thus, metformin does not increase lifespan
by preventing bacterial proliferation. Culture of C. elegans with
Bacillus subtilis increases lifespan (Garsin et al., 2003), suggest-
ing that this microbe is less pathogenic toC. elegans than E. coli.
Metformin increased lifespan of worms cultured on B. subtilis
(+9%, p < 0.001; Figure 2E; Table S2). These findings suggest
that reduced bacterial pathogenicity is not the cause of metfor-
min-induced longevity.
Biguanides Have Bacteriostatic Effects at
Concentrations that Increase Lifespan
Biguanides induced a dose-dependent inhibition of E. coli prolif-
eration (Figures 2F and S2C) and an alteration in bacterial lawn
morphology (Figure 2G). Similar results were obtained with
B. subtilis (Figures S2D–S2F). Thus, metformin can also act as
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Figure 2. Metformin Extending Effects on
C. elegans Lifespan Require Live Bacteria
(A) Metformin shortens lifespan of C. elegans
cultured axenically (i.e., in the absence of E. coli).
(B) Metformin shortens lifespan of C. elegans
cultured on UV-irradiated E. coli (OP50).
(C) Metformin pretreatment of bacteria is sufficient
to extend lifespan.
(D) Metformin extends lifespan in the absence of
E. coli proliferation (blocked by carbenicillin).
(E) Metformin extends lifespan in the presence of
the less pathogenic bacterium Bacillus subtilis.
(F) Retardation of bacterial growth by metformin,
monitored over an 18 hr period.
(G) Biguanide drugs cause altered bacterial lawn
morphology.
(H) Bacterial viability is reduced by carbenicillin
and UV treatment, but not metformin.
(I) Metformin extends lifespan in the presence of
multi-antibiotic resistant E. coli OP50-R26.
See also Figure S2. For statistics, see Table S2.
an antibiotic. Notably, the drug concen-
tration thresholds for bacterial and worm
lifespan effects were similar, and also
pH-dependent (Figures S2G and S2H
and Table S2).
We then asked if the antibiotic effects
of metformin were bacteriocidal or bacte-
riostatic. When subcultured from metfor-
min plates, E. coli showed no reduction
in colony forming units (Figure 2H),
implying that metformin has bacterio-
static rather than bacteriocidal effects.
To probe whether metformin acts via
one of the major, known antibiotic mech-
anisms, we employed the R26 P-group
plasmid that confers resistance to carbe-
nicillin, neomycin, kanamycin, tetracycline, streptomycin, genta-
micin, mercuric ions, and sulfonamides. However, metformin still
extended lifespan in worms on R26-transformed E. coli (39%,
p < 0.001; Figure 2I and Table S2).
What is the property of E. coli whose alteration by metformin
increases worm lifespan? Coenzyme Q (ubiquinone) deficiency
in E. coli increases C. elegans lifespan due to impairment of
bacterial respiration (Saiki et al., 2008). We therefore tested
whether metformin can increase lifespan of worms on Q-defi-
cient ubiG mutant E. coli and found that it does (+20%, p <
0.001; Figure 3A). We then tested whether metformin reduces
respiration rate in E. coli OP50. Although metformin transiently
reduced respiration rate, long-term exposure increased it (Fig-
ure 3B). Taken together, these findings suggest that metformin’s
effect on worm lifespan is not caused by inhibition of bacterial
respiration.
Lipopolysaccharides (LPS) are the major component of the
outer wall of Gram-negative bacteria. The structure of E. coli
LPS can affect C. elegans lifespan (Maier et al., 2010). To test
whether metformin action is dependent upon E. coli LPS type,
we looked at worm lifespan on seven E. coli strains with a variety
230 Cell 153, 228–239, March 28, 2013 ª2013 Elsevier Inc.
of LPS structures. Although effects of metformin on worm life-
span differed between E. coli strains (Figures 3A–3E and S3A
and Table S3), this variation did not correlate with the E. coli
LPS type.
Interestingly, among E. coli strains there was a strong positive
correlation between the capacity of metformin to increase worm
lifespan and to inhibit bacterial growth (R2 = 0.82, p < 0.0007;
Figure 3F). There was no correlation between bacterial metfor-
min sensitivity and effect on worm lifespan in the absence of
metformin (R2 = 9.63 105, p = 0.98; Figure S3B). This suggests
that the capacity of the drug to extendworm lifespan is a function
of the microbial sensitivity to growth inhibition by metformin. To
test this directly, we isolated a metformin-resistant OP50 deriv-
ative (OP50-MR) (Figures 3G and S3C–S3E) that proved to
contain eight mutations (see Extended Experimental Proce-
dures). As predicted, on this strain 50 mM metformin shortened
worm lifespan (37%, p < 0.001; Figure 3H). We conclude that in
metformin-resistant E. coli strains, life-shortening toxic effects
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Figure 3. Metformin Effects on C. elegans
Lifespan Correlate with Effects of Metfor-
min on Bacterial Growth
(A) Metformin extends lifespan in the presence of
respiratory-deficient E. coli strain GD1.
(B) Growth in the presence of metformin does not
impair respiration in E. coli OP50.
(C–E) Effects on lifespan are independent of
bacterial subgroup (B or K-12) and lipopolysac-
charide (LPS) structure. K-12 strains possess
longer LPS structures than B strains and CS2429.
CS2429 is an LPS truncated mutant derived from
isogenic parent strain CS180. HB101 is a B/K-12
hybrid.
(F) Relationship between bacterial growth inhibi-
tion by metformin (50 mM) and effects on lifespan
among different E. coli strains.
(G) OP50-MR E. coli is resistant to growth inhibi-
tion by metformin. This strain also shows cross-
resistance to phenformin (Figures S3C–S3E).
(H) Metformin shortens lifespan in the presence of
OP50-MR.
Error bars represent SEM. *p < 0.05; **p < 0.01;
***p < 0.001. See also Figure S3. For statistics, see
Table S3.
predominate. However, inhibition of
bacterial proliferation per se is not the
cause of worm life extension, as already
shown (Figure 2D; Table S2).
Metformin Disrupts Folate
Metabolism in E. coli
It was recently discovered thatC. elegans
live longer on an E. coli mutant with
reduced folate levels (aroD) (Virk et al.,
2012). Moreover, metformin can de-
crease folate levels in patients (Sahin
et al., 2007). We therefore asked whether
metformin increases worm lifespan by
altering bacterial folate metabolism.
Folates are B-group vitamins whose structure incorporates
a pteridine ring, p-aminobenzoic acid (pABA), and glutamic
acid(s). Folates are typically present as the reduced forms,
dihydrofolate (DHF) and tetrahydrofolate (THF). THF can be
substituted with a variety of one-carbon units (including
formyl and methyl groups) that function as a coenzyme in
metabolic reactions involving transfer of one-carbon moieties
(Figure 4A). These are involved in the biosynthesis of purines
and pyrimidines, in amino acid interconversions, and for the
provision of methyl groups in methylation reactions (Kwon
et al., 2008).
Metformin markedly changed the folate composition in OP50
(Figure 4B), as detected by LC-MS/MS. It increased levels of
5-methyl-THF (+116%, p = 2.5 3 106), 5,10-methylene-THF
(+99%, p = 5.9 3 106), and DHF (+38%, p = 7.1 3 104),
whereas levels of the remaining folates were decreased. It
also increased folate polyglutamylation, particularly n = 6 and
7 glutamates (Figures 4C, S4A, and S4B; Table S4). Folate
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polyglutamylation increases their retention in the cell, and
bioavailability for reactions involving folate-dependent enzymes
(Kwon et al., 2008). By contrast, in the resistant strain OP50-MR,
metformin did not affect polyglutamylation (Figures 4C and S4C),
or DHF levels. 5-Methyl-THF and 5,10-methylene-THF were
still increased (Figure 4B), but by only 29% (p = 0.018) and
17% (p = 0.003). Genome sequencing of OP50-MR revealed
a mutation in glyA, which encodes a folate cycle enzyme.
To explore whether metformin effects on bacterial folate
metabolism affect worm lifespan, we used the antibiotic trimeth-
oprim (TRI) that inhibits dihydrofolate reductase (DHFR). TRI
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Figure 4. Metformin Inhibits Bacterial
Folate Metabolism
(A) The folate and methionine cycles. Metabolites
analyzed, red; enzymes, blue; supplements,
purple. DHF, dihydrofolate; DHFR, dihy-
drofolate reductase; Glu, glutamate; Hcy, homo-
cysteine; Met, methionine; MS, methionine
synthetase; MTHFR, methylenetetrahydrofolate
reductase; pABA, p-aminobenzoic acid; SAH,
S-adenosylhomocysteine; SAMe, S-ad-
enosylmethionine; SAMS, S-adenosylmethionine
synthase; THF, tetrahydrofolate; TRI, trimetho-
prim. Dotted lines represent feedback loops.
(B) Metformin alters folate homeostasis in E. coli
OP50 but not OP50-MR. The values for each
metabolite are the sum of the values for the
different glutamate side chains (1–7) divided by
sum of all folate metabolites measured.
(C) Metformin alters 5-methyl-THF poly-
glutamylation in OP50 but not OP50-MR.
(D) The DHFR inhibitor TRI increases C. elegans
lifespan in a dose-dependent manner. See Fig-
ure S4D for E. coli growth retardation by TRI.
(E) Effects of metformin and TRI on lifespan are
nonadditive, consistent with similar modes of
action.
(F) Principal component analysis (Metaboanalyst)
of OP50 metabolites with TRI and metformin. Note
that TRI abolishes effects of metformin.
Error bars represent SEM. *p < 0.05; **p < 0.01;
***p < 0.001. See also Figure S4. For statistics, see
Table S4.
(0.2, 0.5, and 1 mg/ml) increased lifespan
by 16%, 30%, and 38%, respectively
(p < 0.001) (Figure 4D). By contrast, in
the presence of 50 mM metformin,
0.2 mg/ml TRI caused only a slight
increase in lifespan (+8%, p < 0.001),
whereas at higher concentrations it either
had no effect (0.5 mg/ml TRI, 2%, p =
0.17) or reduced lifespan (1 mg/ml TRI,
19%, p < 0.001; Figure 4E). Such
nonadditivity was recapitulated in the
lack of effect of metformin on metabolic
profiles of OP50 when cotreated with
1 mg/ml TRI (Figures 4F and S4E). These
nonadditive effects of metformin and TRI
imply a sharedmechanism of action, sug-
gesting that altered bacterial folate metabolism by metformin
increases worm lifespan.
Metformin Disrupts C. elegans Methionine Metabolism
To explore whether metformin-induced alterations in microbial
folate metabolism increase host lifespan by altering worm folate
metabolism, we first examined worm folate profiles under stan-
dard culture conditions (agar plates with E. coli OP50). In
worms, as in humans, 5-methyl-THF was the predominant folate
(59%) and treatment with metformin did not alter the ratio of
different folate forms (Figure 5A). However, it did decrease
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glutamate chain length (n = 1–3) (Figures 5B and S5; Table S5),
suggesting a possible change in the activity of folate-dependent
enzymes.
Thus, disruption of microbial folate metabolism increases host
lifespan but with little effect on host folate levels. One possibility
is that products of other E. coli folate-associated pathways influ-
ence C. elegans lifespan. Inhibition of bacterial methionine syn-
thase (MS) causes 5-methyl-THF accumulation via the ‘‘methyl
trap’’ mechanism, so-called because of the irreversible con-
version of 5,10-methylene-THF to 5-methyl-THF (Mato et al.,
2008) (Figure 4A). Consistent with MS inhibition, metformin not
only strongly increased 5-methyl-THF levels but also reduced
levels of THF (14%, p = 0.003) (Figure 4B). Metformin also
impaired the bacterial methionine cycle, causing an 86%
increase in S-adenosylmethionine (SAMe) levels (p = 0.0032)
and a 33% increase of S-adenosylhomocysteine (SAH) (p =
0.055; Figures 4A and 5C), consistent with the lack of homocys-
teine (Hcy) remethylation if MS is inhibited. SAMe, the major
corepressor of genes encoding enzymes of methionine biosyn-
thesis, also inhibits the folate cycle and reduces methionine
production by blocking methylene-THF reductase (MTHFR)
(Banerjee and Matthews, 1990) (Figure 4A). Thus, the accumula-
tion of the substrates SAMe, SAH, 5-methyl-THF, and 5,10-
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(SAH) levels.
(F) Metformin shortens lifespan in S-ad-
enosylmethionine synthase-deficient sams-1
(ok3033) mutants.
Error bars represent SEM. *p < 0.05; **p < 0.01;
***p < 0.001. See also Figure S5. For statistics, see
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methylene-THF, and reduction of the
product THF imply that metformin also
reduces microbial methionine availability.
This suggests that metformin might
increase lifespan by reducing levels of
bacterial-derived methionine in the host.
To explore this, we employed aC. elegans
MS mutant, metr-1(ok521), which cannot
synthesize methionine and is therefore
wholly dependent upon exogenous
methionine (Hannich et al., 2009). In the
absence of metformin, metr-1 did not
increase worm lifespan (p = 0.85; Fig-
ure 5D). Interestingly however, metr-1 did increase lifespan in
the presence of 50 mMmetformin (+67%, p < 0.001; Figure 5D).
Thus,metr-1 sensitizesC. elegans to the life-extending effects of
metformin.
This suggests that microbes are the main source of dietary
methionine, but the worms also synthesize some methionine of
their own using METR-1. Thus, effects of metr-1 on lifespan
are only detected when dietary methionine levels are reduced.
Supporting this scenario, metformin treatment lowered SAMe
levels in C. elegans (72%, p = 0.005) and increased SAH levels
(+181%, p = 0.002; Figure 5E). In summary, in E. coli metformin
increases SAMe and 5-methyl-THF. By contrast, in C. elegans it
decreases SAMe and the SAMe/SAH ratio without affecting
5-methyl-THF levels.
In C. elegans, SAMe is synthesized by the SAMe synthase
SAMS-1, RNAi knockdown of which extends lifespan (Hansen
et al., 2005). Notably, sams-1 RNAi does not increase eat-2
mutant lifespan, suggesting a shared mechanism with eat-2-
induced DR (Ching et al., 2010; Hansen et al., 2005). If metformin
increases lifespan by the same mechanism as loss of sams-1,
then metformin should not increase lifespan in the absence
of sams-1. To test this, we employed a sams-1(ok3033) null
mutant that, as expected, extended lifespan (+35%, p < 0.001;
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Figure 5F). Strikingly, in a sams-1 mutant, metformin reduced
lifespan (38%, p < 0.001), reminiscent of the effect of metfor-
min on eat-2 mutants (Onken and Driscoll, 2010). These results
suggest the possibility that metformin and eat-2-induced DR
act by similar disruptions of methionine-associated functions.
AMP Kinase and SKN-1 Protect C. elegans Against
Metformin Toxicity
Metformin-induced longevity requires the worm AMP-depen-
dent protein kinase (AMPK) (Onken and Driscoll, 2010). This is
consistent with the fact that biguanide drugs activate AMPK
(Hawley et al., 2003). However, if extension ofC. elegans lifespan
by biguanide drugs is mediated by E. coli, why should this effect
require the worm AMPK? To explore this, we first tested whether
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Figure 6. AMP kinase and SKN-1 Protect
Against Biguanide Toxicity
(A) Phenformin increases pAAK-2 levels, sug-
gesting AMPK activation (2-day-old adults).
(B) Phenformin shortens lifespan in aak-2(ok524)
AMPK loss-of-function mutants.
(C) Phenformin does not extend lifespan in skn-
1(zu135) mutants.
(D) AMPK-dependent induction of expression by
phenformin of SKN-1-activated reporter gst-4::gfp
in L4 animals.
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are hypersensitive to growth inhibition by metfor-
min, as measured by the food clearance assay.
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(G) Metformin increases expression of gst-4::gfp
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(I) Life extension by metformin pretreatment of
E. coli is not SKN-1-dependent.
Error bars represent SEM of at least three inde-
pendent biological replicates. *p < 0.05; **p < 0.01;
***p < 0.001. See also Figure S6. For statistics,
see Table S6.
biguanides activate worm AMPK, by
measuring phosphorylation of Thr-172 in
the worm AMPKa subunit AAK-2. Phen-
formin, but not metformin, detectably
increased pAMPK levels (Figures 6A and
S6A), perhaps reflecting the greater
membrane permeability of phenformin.
We then verified the AMPK-dependence
of the effect of biguanides on worm life-
span in the presence of E. coli. Lifespan
in aak-2 mutants was not increased by
either metformin (Figure S6B; Table S6),
as previously noted (Onken and Driscoll,
2010), or phenformin (Figure 6B). In fact,
phenformin reduced lifespan (15%, p <
0.001; Table S6). Notably, the metfor-
min-induced deceleration of the age
increase in mortality rate was still present in aak-2 mutants, but
initial mortality rates were markedly greater (Figure S6C), consis-
tent with increased sensitivity to metformin toxicity.
The life-extending effects of both biguanides also required
the SKN-1 Nrf2 transcription factor (Figures 6C and S6H), and
induced expression of the SKN-1 target gst-4 (glutathione
S-transferase 4) in an AMPK-dependent fashion (Figures 6D
and S6I–S6K), consistent with previous findings (Onken and
Driscoll, 2010). Thus, both biguanides cause AMPK-dependent
activation of SKN-1, and induce detoxification gene expression.
Our findings imply that the impact of metformin on worm life-
span reflects the sum of indirect, E. coli-mediated life-extending
effects and direct life-shortening effects. A possible interpreta-
tion of the AMPK and SKN-1 dependence of biguanide effects
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on lifespan is that these proteins protect worms against drug
toxicity. To test this, we compared growth inhibition by metfor-
min in wild-type and mutant C. elegans using a food clearance
assay. aak-2 and skn-1 but not daf-16 mutants showed
increased sensitivity to growth inhibition by biguanides (Figures
6E, 6F, and S6D). Note that metformin-induced life extension is
not daf-16-dependent (Onken and Driscoll, 2010). We also
observed that metformin induced a similar level of gst-4 expres-
sion in worms on E. coli OP50 and HT115 (+29 and +30%,
respectively) even though the drug increases lifespan only with
the former strain (Figure 6G). These findings further suggest
that aak-2 and skn-1 protect worms against biguanide toxicity.
To test this further, we raised E. coliwith or without metformin,
and then transferred it to metformin-free plates with carbenicillin
to prevent further growth. Carbenicillin does not affect E. coli-
mediated effects of metformin (Figure 2D). Notably, metformin-
pretreated E. coli caused a larger increase in mean lifespan in
wild-type worms than aak-2 worms (+48 and +29%, respec-
tively, p < 0.001, Figure 6H) but not skn-1 worms (+17
and +21%, respectively, p < 0.0001; Figure 6I). Moreover, exten-
sion of lifespan by blocking folate metabolism with 1 mg/ml TRI
(Figure S6E) or by a folate- deficient mutant E. coli aroD also
appeared to be partially aak-2-dependent (Figure S6F). These
results suggest that AMPK-dependence of life extension bymet-
formin is partly due to resistance against drug toxicity, but also
partly to AMPK mediation of microbial effects on the worm. By
contrast, skn-1 activation appears to act solely by protecting
against the life shortening effect of metformin.
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How might SAMe levels regulate
AMPK? Increased levels of SAMe can
inhibit AMPK activation (Martı´nez-Chan-
tar et al., 2006). To probe this we tested
whether longevity induced by sams-1
RNAi is AMPK-dependent, and this
proved to be the case (Figure S6G). This
suggests that metformin increases life-
span at least in part via the AMPK-acti-
vating effects of reduced SAMe levels.
Metformin Does Not Extend
Lifespan on a High Glucose Diet
Metformin is a treatment for hypergly-
cemia caused by diabetes. We wondered
whether metformin is able to provide protection against high
glucose levels, which can shorten worm lifespan (Lee et al.,
2009). In fact, metformin proved unable to extend the lifespan
of worms supplemented with 0.25% or 1% glucose (Figures
7A and S7A; Table S7), but instead shortened lifespan. Next
we tested whether high glucose affected inhibition of bacterial
growth by metformin. Strikingly, glucose supplementation sup-
pressed metformin-induced inhibition of bacterial growth (Fig-
ures S7B–S7D). This may reflect a switch from amino acid-based
to glucose-based metabolism for growth, relieving the need of
glucogenic amino acids (e.g., methionine) as a source of carbon.
Thus, a diet high in glucose can abrogate the beneficial effects
of metformin on lifespan, a finding of potential relevance to
mammals.
DISCUSSION
In this study we have shown how metformin slows aging in
C. elegans by metabolic alteration of the E. coli with which it is
cultured. Metformin disrupts the bacterial folate cycle, leading
to reduced levels of SAMe and decelerated aging in the worm.
Two Mechanisms of Action of Metformin on C. elegans
The effect of metformin on worm lifespan was strongly depen-
dent upon the accompanying microbes. In the presence of
some E. coli strains, metformin increased lifespan, whereas
with other strains or in the absence of microbes it shortened life-
span. This study demonstrates that metformin has both direct
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and indirect effects on C. elegans. Metformin (50 mM) acts
directly to shorten worm lifespan, likely reflecting drug toxicity,
and indirectly to increase lifespan by impairing microbial folate
metabolism. The actual effect of metformin on lifespan depends
on whether direct or indirect effects predominate. Given metfor-
min-sensitive E. coli strains (e.g., OP50), drug treatment impairs
folate metabolism and slows aging. But given metformin-resis-
tant strains (e.g., OP50-MR), folate metabolism is less affected,
the toxic effect predominates, and lifespan is shortened. It is
possible that in other host organisms the capacity for metformin
to slow aging is also microbiome-dependent. For example, the
recent observation that metformin activates AMPK but does
not increase lifespan in Drosophila (Slack et al., 2012) might
reflect the presence of metformin-resistant microbiota.
Our findings imply that life-extending effects of metformin are
not due to rescue from proliferation-mediated bacterial pathoge-
nicity. Instead, the drug alters bacterial metabolism, leading to
a state of nutritional restriction in the worm, which increases
lifespan. Consistent with this, as under DR, concentrations of
biguanides that increase lifespan also reduce egg laying rate
(Onken and Driscoll, 2010) (Figures S1A and S1B) and reduce
the rate of increase in age-specific mortality (Figures 1D and
S6C) (Wu et al., 2009).
It was previously demonstrated that AMPK-dependent acti-
vation of SKN-1 is essential for metformin benefits on health
span and lifespan (Onken and Driscoll, 2010). Our findings
show that AMPK and SKN-1 promote resistance to biguanide
toxicity, and imply it is for this reason that in their absence
drug-induced life extension is not seen. However, AMPK (but
not SKN-1) is also required for the full microbe-mediated life
extension (Figure 6H).
Metformin Effects on Methionine Metabolism in E. coli
and C. elegans
We investigated the likely bacterial target of metformin, first
ruling out DHF reductase as a target (Figures S4E–S4G). Instead,
metformin induction of a methyl trap, in which 5-methyl-THF
accumulates, is consistent with lowered MS activity (Nijhout
et al., 2004) and therefore attenuated methionine biosynthesis.
Moreover, metformin also increases bacterial levels of SAMe,
which is known to inhibit transcription of genes involved inmethi-
onine biosynthesis (Banerjee and Matthews, 1990). Studies in
mammalian liver cells show that SAMe can act both as an allo-
steric activator of SAMS and a feedback inhibitor of MTHFR
leading to reduced levels of methionine. In addition, increased
levels of 5-methyl-THF block methyltransferases (e.g., glycine
N-methyltransferase) (Mato et al., 2008). This provides a potential
explanation for the observed rise of SAMe in addition to MS inhi-
bition by metformin, and strongly suggest that it reduces bacte-
rial methionine levels (Figure 7C).
Consistent with this, treating the C. elegans/E. coli system
with metformin caused a 5-fold decrease in SAMe levels and
a drop in the SAMe/SAH ratio in the worm. Moreover, mutation
of the worm MS gene metr-1 enhanced metformin-induced life
extension, again consistent with MS inhibition in metformin-
treated E. coli, and also with methionine restriction as a mecha-
nism of worm life extension. The latter is further supported
by the inability of metformin to extend the lifespan of sams-1
mutant worms, which have a 65% decrease in SAMe levels
(Walker et al., 2011).
Both sams-1 RNAi and metformin increase lifespan in wild-
type but not eat-2 (DR) mutants worms, and both treatments
are thought to recapitulate the effects of DR (Hansen et al.,
2005; Onken and Driscoll, 2010). Indeed, metformin induces
a DR-like state that, similarly to decreased levels of sams-1 by
RNAi, reduces brood size, delays reproductive timing, and
increases lifespan independently of the transcription factor
DAF-16/FoxO but not in eat-2 DR mutants (Onken and Driscoll,
2010). Also, sams-1 mRNA levels are reduced 3-fold in eat-2
mutants (Hansen et al., 2005). Similar DR-like phenotypes,
including reduced body size, were observed in our study when
using phenformin (Figures S1A–S1D). Moreover, restriction of
dietary methionine can extend lifespan in fruit flies and rodents
(Grandison et al., 2009; Orentreich et al., 1993).
Takenwith these observations, our findings suggest a potential
common mechanism underlying the action of metformin, knock-
down of sams-1 and DR, which will be interesting to investigate
in future studies. Potential mechanisms by which reduced SAMe
might increase lifespan include reduced protein synthesis and
altered fat metabolism (Ching et al., 2010; Hansen et al., 2005;
Walker et al., 2011). Additionally, reduced SAMe/SAH ratio, as
ameasure of reducedmethylation potential, could modulate life-
span via histone methylation (i.e., epigenetic effects). One possi-
bility is that the relative abundance of metabolites such as SAMe
allows the cell to assess its energy state and respond accord-
ingly, creating a link between diet, metabolism and gene expres-
sion to modulate physiology and consequently lifespan.
Metformin and Gut Microbiota in Humans
Our findings are of potential relevance to mammalian biology
and human health. Bacteria in the human gut play a central
role in nutrition and host biology, and affect the risk of obesity
and associatedmetabolic disorders such as diabetes, inflamma-
tion, and liver diseases (Cani and Delzenne, 2007). Our finding
that metformin influences C. elegans aging by altering microbial
metabolism raises the possibility that this drug might similarly
influence mammalian biology by affecting microbial metabolism
or composition.
Metformin is the most prescribed drug to treat T2D, with
doses ranging from 500–2,500 mg/day (Scarpello and Howlett,
2008). Drug concentration in the jejunum is 30- to 300-fold
higher than in the plasma in metformin recipients (Bailey
et al., 2008) and concentrations above 20 mM have been
detected in the intestinal lumen after administration of 850 mg
metformin (Proctor et al., 2008). Interestingly, common side
effects include gastrointestinal disorders (e.g., bloating and
diarrhea) (Bytzer et al., 2001), reduced folate, and increased
homocysteine levels (Sahin et al., 2007). Similarly, we find that
metformin impairs bacterial folate metabolism and reduces
host SAMe/SAH ratio.
Factors causing perturbation of the microbiome (dysbiosis),
e.g., obesity, a high-fat diet, and antibiotics, often lead to meta-
bolic dyshomeostasis in the host (Delzenne et al., 2011; Nichol-
son et al., 2012) e.g., due to release of proinflammatory microbial
LPS into the bloodstream. Our data show that the effects of
metformin are bacterial strain-dependent but independent of
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LPS. One possibility is that metformin might promote a better
balance of gut microbiota species. We were able to develop
a metformin-resistant bacterial strain that confers benefits to
the host (Figure S3F) suggesting that long-term administration
of metformin could benefit the host even after treatment is
ceased. Indeed, metformin administration to rats causes a
change in the composition of the microbiome (Pyra et al.,
2012), although it remains unclear what effect this has upon
the host. Moreover, the antibiotic norfloxacin can induce alter-
ation of mouse gut microbiome that has beneficial effects, e.g.,
enhanced glucose tolerance (Membrez et al., 2008).
Lowering dietary glucose can benefit humans with metabolic
syndrome or T2D (Venn and Green, 2007). Diet strongly influ-
ences the metabolism of the human microbiota (Turnbaugh
et al., 2009). We have found that elevated dietary glucose
suppresses the effects of metformin on bacterial growth and
worm lifespan. This suggests that a high-sugar diet might impair
microbe-mediated benefits of metformin.
Overall, our findings point to the potential therapeutic efficacy
of drugs that alter gut microbiota, particularly to prevent or treat
metabolic disease (Delzenne et al., 2011). In addition, it under-
scores the value of C. elegans as a model to study host-microbe
interactions.
E. coli as Food Source and Microbiome for C. elegans
Mammals, including humans, coexist with intestinal microbes in
a relationship that includes elements of commensalism, symbi-
osis, and pathogenesis, and microbiota strongly influences
host metabolism (Delzenne et al., 2011; Nicholson et al., 2012).
Several observations suggest that in at least some respects
E. coli could act as microbiome for C. elegans. Although worms
can be cultured on semidefined media in the absence of E. coli
(axenically), such media do not support normal growth and
fertility. C. elegans seems to require live microbes for normal
growth, reproduction, and aging (Lenaerts et al., 2008; Smith
et al., 2008).
However, unlike microbiota and their mammalian hosts, E. coli
is the principal food source for C. elegans. Studies of GFP-
labeled E. coli imply that in late stage larvae (L4), bacterial cells
are largely broken down by the pharynx prior to entering the
intestine (Kurz et al., 2003), although by day 2 of adulthood intact
E. coli are visible in the intestine (Labrousse et al., 2000). In
senescent worms, E. coli contribute to the demise of their
host, clogging the lumen of the alimentary canal and invading
the intestine (Garigan et al., 2002; Labrousse et al., 2000; McGee
et al., 2011). Thus, it appears that in early life C. elegans and
E. coli exist in a predator-prey relationship, whereas in late life
the tables are turned. But it remains possible that metabolic
activity in intact or lysed E. coli within the worm contributes to
intestinal function and host metabolism throughout life.
Presumably, C. elegans has evolved in the constant presence
of metabolically active intestinal microbes. We postulate that,
consequently, intestinal function requires their presence. Thus,
it may only be possible to fully understand C. elegans metabo-
lism as it operates within the C. elegans/E. coli holobiont
(Zilber-Rosenberg and Rosenberg, 2008). Our account of how
metformin impacts on the two organisms is consistent with
this view.
EXPERIMENTAL PROCEDURES
Strains and Culture Conditions
Nematode and bacterial strains used and generated in this study are
described in the Extended Experimental Procedures. Where indicated, molten
NGM agar was supplemented with drugs. Axenic plates were prepared as
previously described (Lenaerts et al., 2008).
Lifespan Analysis
This was performed as follows, unless otherwise indicated. Briefly, trials were
initiated by transfer of L4-stage worms (day 0) on plates supplemented with
15 mMFUdR. Statistical significance of effects on lifespan was estimated using
the log rank test, performed using JMP, Version 7 (SAS Institute).
GST-4::GFP Fluorescence Quantitation
Animals were raised from L1 stage on control or drug-treated plates. Quanti-
fication of GFP expression at the L4 stage was carried out using a Leica
DMRXA2 epifluorescence microscope, an Orca C10600 digital camera
(Hamamatsu, Hertfordshire, UK), and Volocity image analysis software (Impro-
vision, UK). GFP intensity was measured as the pixel density in the entire
cross-sectional area of each worm from which the background pixel density
was subtracted (90 worms per condition).
Bacterial Growth Assay
Liquid bacterial growth was performed in microtiter plates containing the
respective bacterial strain (previously grown overnight in LB and diluted
1,000-fold) and drugs in 200 ml of LB at pH 7.0. Absorbance (OD 600 nm)
was measured every 5 min over an 18 hr period with shaking at 37C using
a Tecan Infinite M2000 microplate reader and Magellan V6.5 software. For
colony forming unit counts, see Extended Experimental Procedures.
Bacterial Respiration
This was measured in a Clark-type oxygen electrode (Rank Brothers,
Cambridge, UK) in a 1 ml stirred chamber at 37C (Lenaerts et al., 2008).
Metabolite Analysis by LC-MS/MS
Bacterial and nematode metabolite analysis was performed as described in
Extended Experimental Procedures.
Metabolomic Principal Component Analysis
Raw LC-MS/MS spectral data were uploaded into MetaboAnalyst. To avoid
propensity to data overfitting, PCA analysis was used to create the 2D
analysis plot.
Western Blotting
Briefly, phosphorylation of AAK-2 subunit (pAMPKa) was detected using
pAMPKa (Cell Signaling) at a 1:1,000 dilution. Films were scanned and the
density of each band or the entire lane was quantified by densitometry using
ImageQuant TL (GE Healthcare Europe Gmb, UK).
Food Clearance Assay
The effect of biguanide compounds on C. elegans physiology was monitored
from the rate at which 50% of the E. coli food suspension was consumed, as
a read out for C. elegans growth, survival, or fecundity.
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